drugset / Trial / NCT07635914
A Study Evaluating Aprocitentan Tablets(SYH9108) for the Treatment of Resistant Hypertension
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Aprocitentan tablets are currently the only endothelin dual receptor antagonist approved internationally for the treatment of resistant hypertension.This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to evaluate the efficacy and safety of aprocitentan tablets(SYH9108) in patients with treatment-resistant hypertension (rHTN)
Timeline
- Start
- 2026-05-31
- Primary completion
- 2029-12-28
- Completion
- 2030-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aprocitentan | Small molecule | — | Oral |